YTHDF1 and neoplasm: Furthermore, the combination treatment of YTHDF1 knockdown and anti-PD-L1 led to a complete tumor regression that overwhelmed the monotherapy groups evaluated, indicating that YTHDF1 depletion in combination with an ICI is a novel strategy to enhance the therapeutic efficacy [107].